Experimental combo for tough pancreatic cancer shows early promise
NCT ID NCT06199466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether adding the experimental drug YL-13027 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe for people with advanced pancreatic cancer that no longer responds to treatment. Only 4 participants were enrolled before the study was stopped. The goal was to find the safest dose and see if the combination shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia